Stief Thomas W
Department of Clinical Chemistry, University Hospital Giessen & Marburg, Germany.
Drug Target Insights. 2007;2:83-96. Epub 2007 Mar 22.
Phospholipases A(2) (PLA(2)) are aggressive enzymes that can destroy phospholipids of cell membranes. The resulting cell fragments trigger the kallikrein-mediated contact phase of coagulation. The aim of the present study was to expose citrated whole blood to PLA(2) and to quantify thrombin generation in recalcified plasma.
Normal citrated blood was exposed to bovine pancreatic or snake PLA(2), lipopolysaccharide (LPS), or zymosan A for 30-45 min (RT). After centrifugation the plasma samples were recalcified (10 + 1) with 250 mM CaCl(2) in the recalcified coagulation activity assay (RECA). After 0-45 min coagulation reaction time (CRT at 37°C) 1.6 M arginine (final test concentration) was added to stop hemostasis activation and to depolymerize non-crosslinked fibrin. The generated thrombin activity was chromogenically determined.
100 ng/ml bovine pancreatic or snake PLA(2) generates about 0.2-0.8 IU/ml thrombin after 15 min CRT. This thrombin generation is similar as that induced by 200 ng/ml LPS or 20 μg/ml zymosan A. Up to 60 ng/ml bovine pancreatic PLA(2) the generated thrombin activity is proportional to the PLA(2) activity used; 1 μg/ml PLA(2) induces much less thrombin, but PLA(2) at 10 μg/ml again results into thrombin generation of 0.1-3 IU/ml at 10-15 min CRT. As control, in pooled normal citrated plasma there is no significant change in thrombin generation when exposed to up to 10 μg/ml bovine pancreatic PLA(2).
Elevated plasmatic PLA(2) activities (occurring e.g. in trauma, pancreatitis, or sepsis) activate the blood hemostasis system resulting in pathologic disseminated intravascular coagulation (PDIC). It is suggested to diagnose these life threatening states as early as possible, screening all patients for plasmatic thrombin activity.
磷脂酶A(2)(PLA(2))是一种具有侵袭性的酶,能够破坏细胞膜中的磷脂。产生的细胞碎片会触发激肽释放酶介导的凝血接触阶段。本研究的目的是将枸橼酸化全血暴露于PLA(2)中,并对重新钙化血浆中的凝血酶生成进行定量。
将正常枸橼酸化血液暴露于牛胰腺或蛇PLA(2)、脂多糖(LPS)或酵母聚糖A中30 - 45分钟(室温)。离心后,在重新钙化凝血活性测定(RECA)中用250 mM氯化钙将血浆样本重新钙化(10 + 1)。在0 - 45分钟的凝血反应时间(37°C下的CRT)后,加入1.6 M精氨酸(最终测试浓度)以停止止血激活并使非交联纤维蛋白解聚。通过显色法测定生成的凝血酶活性。
在15分钟的CRT后,100 ng/ml牛胰腺或蛇PLA(2)产生约0.2 - 0.8 IU/ml的凝血酶。这种凝血酶生成与200 ng/ml LPS或20 μg/ml酵母聚糖A诱导的情况相似。在高达60 ng/ml牛胰腺PLA(2)的情况下,生成的凝血酶活性与所使用的PLA(2)活性成正比;1 μg/ml PLA(2)诱导的凝血酶要少得多,但10 μg/ml的PLA(2)在10 - 15分钟的CRT时再次导致0.1 - 3 IU/ml的凝血酶生成。作为对照,在混合的正常枸橼酸化血浆中,暴露于高达10 μg/ml牛胰腺PLA(2)时凝血酶生成没有显著变化。
血浆PLA(2)活性升高(例如在创伤、胰腺炎或败血症中出现)会激活血液止血系统,导致病理性弥散性血管内凝血(PDIC)。建议尽早诊断这些危及生命的状态,对所有患者进行血浆凝血酶活性筛查。